Glycogen Metabolism May Play a Key Role in Pulmonary Fibrosis

Currently, there are only two anti-fibrotic drugs endorsed by the FDA for the treatment of pulmonary fibrosis. Although both drugs slow the disease’s progression, neither treatment can completely stop or reverse the lung damage, highlighting the need for novel therapeutics. A recently published study in Nature Communications suggests that glycogen could be an important therapeutic target.